Premium
Differentiation of high‐risk stage I and II colon tumors based on evaluation of CAV1 gene expression
Author(s) -
Kitowska Agnieszka,
Wesserling Martyna,
Seroczynska Barbara,
Szutowicz Andrzej,
Ronowska Anna,
Peksa Rafal,
Pawelczyk Tadeusz
Publication year - 2015
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23995
Subject(s) - medicine , colorectal cancer , stage (stratigraphy) , immunohistochemistry , oncology , gene expression , survival rate , real time polymerase chain reaction , overall survival , cancer , pathology , gene , cancer research , biology , genetics , paleontology
Background Several molecular markers are currently being investigated for their prognostic or predictive value in colorectal cancer. One of the genes proposed, as a potential molecular marker in CRC is CAV1 . Methods The level of CAV1 expression was investigated in low‐stage (I and II TNM) colon cancers using Real‐Time PCR and immunohistochemistry. Results The level of CAV1 expression increased in tumors characterized by greater depths of invasiveness. The CAV1 expression level detected in tumors with a depth of invasion at stage T4 was significantly higher compared to that in T2 ( P = 0.01) and T3 ( P = 0.003) lesions. The length of a patient's survival depended on CAV1 expression level; the 10‐year survival rate for patients with elevated expression of CAV1 was ∼59% compared with 91% for patients with reduced or unchanged expression of CAV1 ( P = 0.007). The overall survival rate of patients with T3 + T4 lesions was significantly lower ( P = 0.006) for patients with tumor displaying elevated CAV1 expression compared with patients with reduced or unchanged CAV1 expression. Conclusions Evaluation of CAV1 expression offers valuable prognostic information for patients with colorectal cancer, and could be used to select patients with stage I or II disease, who are at increased risk of unfavorable outcomes. J. Surg. Oncol. 2015; 112:408–414 . © 2015 Wiley Periodicals, Inc.